Prenetics Global Limited (NASDAQ:PRE) Sees Large Growth in Short Interest

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 41,900 shares, a growth of 23.6% from the November 30th total of 33,900 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average trading volume of 14,000 shares, the short-interest ratio is currently 3.0 days.

Prenetics Global Stock Down 0.5 %

NASDAQ PRE traded down $0.03 on Tuesday, reaching $5.80. 10,471 shares of the stock traded hands, compared to its average volume of 47,859. Prenetics Global has a 12 month low of $2.85 and a 12 month high of $7.84. The firm’s fifty day simple moving average is $4.90 and its 200 day simple moving average is $5.11. The company has a market cap of $52.99 million, a price-to-earnings ratio of -1.45 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings results on Monday, October 7th. The company reported ($0.88) EPS for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. The business had revenue of $5.94 million during the quarter. As a group, equities research analysts forecast that Prenetics Global will post -3.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 target price on shares of Prenetics Global in a research report on Wednesday, December 4th.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.